Acute Myeloid Leukemia and Related Precursor Cell Neoplasms: Complete ICD-11 Coding Guide

1. Introduction

Acute myeloid leukemia (AML) and related precursor cell neoplasms represent a heterogeneous group of hematologic malignancies characterized by uncontrolled clonal proliferation of immature myeloid cells in the bone marrow, peripheral blood, and occasionally in other tissues. This condition constitutes an oncologic emergency that requires rapid diagnosis and immediate therapeutic intervention.

AML is the most common acute leukemia in adults, with an incidence that progressively increases with age. It represents approximately three-quarters of all acute leukemias diagnosed in patients over 20 years of age. The disease affects the hematopoietic system aggressively, resulting in progressive bone marrow failure that manifests through anemia, thrombocytopenia, and neutropenia, significantly compromising patients' quality of life and survival.

The impact on public health is considerable, since AML requires intensive and prolonged treatment, involving multiple hospitalizations, aggressive chemotherapy, and frequently bone marrow transplantation. Associated morbidity and mortality remain elevated, especially in elderly patients or those with significant comorbidities. Healthcare costs are substantial, including intensive care, transfusional support, broad-spectrum antibiotic therapy, and specific targeted therapies.

Correct coding using ICD-11 is fundamental for accurate epidemiologic registration, hospital resource planning, allocation of specialized treatments, clinical research, and health statistics. Appropriate classification allows for outcome monitoring, comparison of therapeutic protocols, and development of evidence-based health policies for this complex and potentially fatal condition.

2. Correct ICD-11 Code

Code: 2A60

Description: Acute myeloid leukemia and related precursor cell neoplasms

Parent category: Neoplasms of hematopoietic or lymphoid tissues

Official definition: Acute myeloid leukemia is characterized by clonal expansion of myeloid blasts in peripheral blood and bone marrow. Clinical manifestations include fever, pallor, anemia, hemorrhages, and recurrent infections.

This code encompasses a spectrum of acute myeloid neoplasms that share fundamental characteristics: the presence of immature blastic cells of myeloid lineage in a proportion equal to or greater than 20% in bone marrow or peripheral blood, according to criteria established by the World Health Organization. The code covers not only AML proper, but also related precursor cell neoplasms that present similar biological and clinical characteristics.

The ICD-11 classification for this code recognizes the complexity and molecular heterogeneity of AML, allowing specific subcategories that reflect distinct genetic, cytogenetic, and morphological alterations. This modern approach facilitates communication among healthcare professionals, researchers, and managers, ensuring uniformity in documentation and statistical treatment of global epidemiological data related to these aggressive hematologic neoplasms.

3. When to Use This Code

Code 2A60 should be used in specific clinical situations where there is diagnostic confirmation of acute myeloid leukemia or related precursor neoplasms:

Scenario 1: Patient with pancytopenia and confirmed myeloid blasts A 58-year-old patient presents with progressive fatigue, spontaneous ecchymoses, and recurrent fever for three weeks. The complete blood count reveals anemia (hemoglobin 7.5 g/dL), thrombocytopenia (30,000/mm³), and leukocytosis with 35% blasts in peripheral blood. The bone marrow aspirate confirms hypercellularity with 60% myeloid blasts positive for myeloperoxidase. Immunophenotyping demonstrates expression of CD13, CD33, and CD117. This presentation characterizes AML and justifies code 2A60.

Scenario 2: AML with recurrent cytogenetic alterations A 32-year-old young patient diagnosed with acute leukemia where cytogenetic analysis reveals translocation t(8;21)(q22;q22), resulting in RUNX1-RUNX1T1 gene fusion. Even with blast count close to 20%, this specific genetic alteration is diagnostic of AML with recurrent cytogenetic abnormalities, fitting perfectly within code 2A60 with its specific subcategories.

Scenario 3: Myeloid sarcoma (granulocytic tumor) Patient presents with a tumor mass in the orbital region with biopsy revealing infiltration by myeloid blastic cells. Even without initial involvement of bone marrow or peripheral blood, this myeloid sarcoma (also called chloroma) represents an extramedullary manifestation of AML and should be coded as 2A60.

Scenario 4: AML related to prior therapy A 65-year-old patient previously treated for lymphoma with chemotherapy containing alkylating agents develops acute leukemia after four years. Evaluation confirms AML with morphologic and genetic features typical of therapy-related disease (abnormalities of chromosomes 5 and 7). This specific subtype of secondary AML uses code 2A60.

Scenario 5: Acute promyelocytic leukemia Patient presents with severe hemorrhagic manifestations with disseminated intravascular coagulation. The bone marrow aspirate reveals abnormal promyelocytes with dense cytoplasmic granules. Molecular analysis confirms translocation t(15;17) with PML-RARA fusion. This specific AML variant, despite its unique characteristics and differentiated treatment, is coded within 2A60 with appropriate specifier.

Scenario 6: AML with minimal or absent maturation Patient with acute leukemia where blasts show minimal or absent myeloid differentiation on morphologic examination, but immunophenotyping and cytochemistry confirm myeloid origin through expression of specific markers such as MPO, CD13, or CD33. Even with undifferentiated morphologic features, the diagnosis of AML is established and code 2A60 is appropriate.

4. When NOT to Use This Code

There are specific clinical situations where code 2A60 should not be applied, even if there are significant hematological alterations:

Myelodysplastic syndromes (MDS): When the blast count in bone marrow is less than 20% and the clinical presentation is characterized by chronic cytopenias with dysplasia in one or more cell lines, without progression to acute leukemia, specific codes for MDS should be used. The fundamental difference lies in the percentage of blasts and the less aggressive clinical course.

Chronic myeloproliferative neoplasms: Conditions such as chronic myeloid leukemia in chronic phase, polycythemia vera, essential thrombocythemia, or primary myelofibrosis should not be coded as 2A60, even if they present with leukocytosis or bone marrow alterations. These diseases have distinct pathophysiology, clinical presentation, and treatment. Only when they progress to blastic transformation (blastic crisis) can they justify coding related to acute leukemia.

Acute lymphoblastic leukemia (ALL): When blasts are of lymphoid origin (B or T lymphoblasts), confirmed by immunophenotyping showing markers such as CD19, CD10, CD79a (B lineage) or CD3, CD7, CD5 (T lineage), the appropriate code belongs to the category of acute lymphoid leukemias, not 2A60.

Leukemoid reactions: Marked leukocytosis with left shift secondary to severe infections, intense inflammatory processes, or other reactive conditions does not constitute leukemia. The absence of significant blasts and the clinical context of response to an identifiable stimulus differentiate these conditions.

Lymphomas with secondary bone marrow involvement: When an established lymphoma presents with bone marrow infiltration, but without transformation into acute leukemia, the primary code should reflect the type of lymphoma, not AML.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of AML requires rigorous laboratory confirmation. Initially, evaluate the complete blood count seeking cytopenias, leukocytosis, or presence of circulating blasts. The differential count is essential to quantify blasts in peripheral blood.

The bone marrow aspirate constitutes the fundamental diagnostic examination, and must demonstrate 20% or more myeloid blasts. Bone marrow biopsy complements the evaluation, providing information about cellularity and bone marrow architecture.

Cytochemical studies identify specific characteristics of myeloid blasts, such as positivity for myeloperoxidase or nonspecific esterases. Immunophenotyping by flow cytometry is mandatory, identifying cell surface markers that confirm myeloid lineage (CD13, CD33, CD117, MPO) and exclude lymphoid origin.

Cytogenetic analysis by conventional karyotype or FISH (fluorescence in situ hybridization) detects recurrent chromosomal alterations with prognostic and therapeutic implications. Molecular studies identify relevant gene mutations (FLT3, NPM1, CEBPA, among others) that influence risk stratification and therapeutic decisions.

Step 2: Verify specifiers

After confirming the diagnosis of AML, identify specific characteristics that may require subcategories within code 2A60:

Determine whether there are specific recurrent cytogenetic alterations (balanced translocations such as t(8;21), inv(16), t(15;17)) that define subtypes with distinct biological characteristics. Verify whether AML is de novo (without prior history of hematologic disease) or secondary to previous treatment or evolution from myelodysplastic syndrome.

Evaluate morphologic characteristics according to FAB (Franco-American-British) classification when relevant: M0 (minimal differentiation), M1 (without maturation), M2 (with maturation), M3 (promyelocytic), M4 (myelomonocytic), M5 (monocytic), M6 (erythroid), M7 (megakaryoblastic).

Identify specific molecular mutations that may define distinct entities or have important prognostic implications. Determine disease status: initial diagnosis, relapse, or refractory disease.

Step 3: Differentiate from other codes

Myeloproliferative neoplasms: These conditions are characterized by excessive proliferation of mature or maturing myeloid cells, without differentiation blockade. The blast count remains below 20%. The clinical course is typically chronic, in contrast to the acute presentation of AML.

Myelodysplastic syndromes: Present with morphologic dysplasia in one or more cell lineages with persistent cytopenias, but blasts below 20%. Progression is generally more indolent compared to AML, although they may eventually transform into acute leukemia.

Myelodysplastic and myeloproliferative neoplasms: Combine characteristics of dysplasia and proliferation, such as chronic myelomonocytic leukemia. They are distinguished from AML by blast count below 20% and less aggressive clinical presentation, with more prolonged course.

Step 4: Required documentation

Adequate documentation must include:

Mandatory checklist:

Complete blood count with differential count and blast percentage
Bone marrow aspirate result with blast percentage and morphologic description
Immunophenotyping report confirming myeloid lineage
Cytogenetic result with description of chromosomal alterations
Molecular studies when available (relevant mutations)
Classification of AML subtype according to WHO criteria
Disease status (new diagnosis, relapse, refractory)
History of previous treatment or prior hematologic disease
Clinical manifestations present (fever, bleeding, infections)
Assessment of comorbidities and performance status

Clearly record the date of diagnosis, methodology of confirmatory examinations, and interpretation of results by a qualified hematologist or hematopathologist.

6. Complete Practical Example

Clinical Case:

A 52-year-old male patient, previously healthy, seeks medical care with a complaint of progressive intense fatigue for six weeks, associated with dyspnea on minimal exertion, intermittent evening fever, and spontaneous ecchymoses on lower extremities. He also reports recurrent epistaxis over the past two weeks and gingival bleeding when brushing teeth.

On physical examination: marked cutaneous-mucosal pallor, petechiae on lower extremities and trunk, ecchymoses at different stages of evolution, discrete hepatomegaly (liver palpable 3 cm below the right costal margin), and moderate splenomegaly. Axillary temperature of 38.2°C. Absence of palpable lymphadenomegaly.

Initial complete blood count reveals: hemoglobin 6.8 g/dL, hematocrit 20%, leukocytes 45,000/mm³ with 42% blasts, neutrophils 15%, lymphocytes 3%, platelets 18,000/mm³. Peripheral blood smear shows medium to large-sized blastic cells with elevated nucleus-to-cytoplasm ratio, fine chromatin, and prominent nucleoli.

Bone marrow aspirate demonstrates hypercellular marrow with 68% myeloid blasts, reduction of erythroid and megakaryocytic series. Cytochemistry positive for myeloperoxidase in 55% of blasts. Flow cytometry immunophenotyping confirms CD34+, CD117+, CD13+, CD33+, MPO+ blasts, negative for lymphoid markers.

Conventional cytogenetics identifies normal karyotype. Molecular analysis by PCR reveals FLT3-ITD mutation and NPM1 mutation. Absence of recurrent translocations. Bone marrow biopsy confirms intense hypercellularity with replacement by blastic population.

Step-by-Step Coding:

Criteria Analysis:

Presence of myeloid blasts ≥20% in bone marrow (68%) and peripheral blood (42%) - diagnostic criterion met
Confirmation of myeloid lineage by immunophenotyping (CD13+, CD33+, MPO+) - lineage confirmed
Exclusion of lymphoid leukemia (negative lymphoid markers) - differential established
Absence of specific recurrent cytogenetic abnormalities - AML without favorable cytogenetic abnormalities
De novo disease (without prior MDS history or antineoplastic therapy) - characteristic established

Code selected: 2A60 - Acute myeloid leukemia and related precursor cell neoplasms

Complete justification: The patient presents with a typical acute leukemia clinical picture with constitutional symptoms (fever, fatigue), manifestations of bone marrow failure (symptomatic anemia, hemorrhagic phenomena from thrombocytopenia, infection susceptibility from neutropenia), and organomegaly. Unequivocal laboratory confirmation through bone marrow aspirate with >20% myeloid blasts, immunophenotyping confirming myeloid lineage, and exclusion of other hematologic neoplasms fully justifies code 2A60.

This is de novo AML without favorable cytogenetic abnormalities, with intermediate-risk molecular mutations (FLT3-ITD) and favorable mutations (mutated NPM1), classified as intermediate risk according to current prognostic stratification.

Applicable complementary codes:

Codes for complications: severe anemia, severe thrombocytopenia, febrile neutropenia if applicable
Codes for procedures: antineoplastic chemotherapy, transfusional support
Additional morphologic codes if registry system requires subtype specification

7. Related Codes and Differentiation

Within the Same Category:

Myeloproliferative neoplasms Use myeloproliferative neoplasm codes when there is proliferation of mature or maturing myeloid cells, with blasts <20%, chronic course and specific features such as presence of JAK2 V617F mutation (polycythemia vera, essential thrombocythemia), BCR-ABL1 (chronic myeloid leukemia) or PDGFRA/PDGFRB gene alterations. The main difference lies in cell maturity, blast percentage and indolent versus aggressive clinical course.

Myelodysplastic syndromes Use specific codes for MDS when blasts <20% in bone marrow, presence of significant dysplasia in one or more cell lines, persistent cytopenias and generally more prolonged course. The fundamental difference is the blast percentage and the predominance of dysplastic features over blastic proliferation. Patients with MDS may eventually progress to AML, at which point the coding changes to 2A60.

Myelodysplastic and myeloproliferative neoplasms Code in this category when there is overlap of dysplastic and proliferative features, such as in chronic myelomonocytic leukemia, with blasts <20%, persistent monocytosis and dysplasia in multiple cell lines. The difference versus AML lies in the blast count below 20% and mixed clinical-laboratory phenotype.

Differential Diagnoses:

Leukemoid reactions may mimic leukemia, but present with leukocytosis with left shift without significant blasts, clinical context of infection or inflammation and resolution with treatment of the underlying condition.

Acute lymphoblastic leukemia differs by the lymphoid origin of blasts, confirmed by immunophenotyping showing B or T cell markers, absence of myeloperoxidase and distinct morphological features.

Bone marrow aplasia presents with pancytopenia without blasts, hypocellular marrow (not hypercellular) and absence of clonal neoplastic population.

8. Differences with ICD-10

In ICD-10, acute myeloid leukemia was coded primarily as C92.0 (Acute myeloid leukemia), with limited subdivisions based mainly on morphological characteristics.

ICD-11 introduces significant changes with code 2A60, reflecting advances in knowledge of AML molecular biology and genetics. The new classification incorporates specific cytogenetic and molecular alterations as primary diagnostic criteria, recognizing that some specific translocations define disease entities even with blast count below the traditional 20% cutoff.

The ICD-11 system allows more detailed subcategorization based on recurrent genetic abnormalities, therapy-related AML, AML with myelodysplasia-related alterations, and myeloid sarcoma as a specific entity. This approach aligns better with modern World Health Organization classifications.

The practical impact includes greater precision in epidemiological recording, better correlation with prognosis and treatment, facilitates clinical research by allowing grouping of patients with similar biological characteristics, and improves international communication about these diseases. The transition requires training of coders and health professionals to understand the new criteria based on molecular biology, not just morphology.

9. Frequently Asked Questions

How is acute myeloid leukemia diagnosed?

Diagnosis requires a multidisciplinary approach combining clinical, laboratory, and specialized evaluation. It begins with a complete blood count that generally reveals cytopenias and the presence of circulating blasts. The definitive test is bone marrow aspiration (myelogram), which should demonstrate 20% or more myeloid blasts. Confirmation of myeloid lineage requires immunophenotyping by flow cytometry, identifying specific markers. Cytogenetic and molecular studies are essential for complete classification, risk stratification, and therapeutic planning. The complete diagnostic process typically takes from a few days to two weeks, depending on the complexity of molecular testing.

Is treatment available in public health systems?

In many countries, public health systems offer treatment for AML, including induction and consolidation chemotherapy, transfusional support, and antibiotic therapy. The availability of bone marrow transplantation, specific targeted therapies, and more modern medications varies significantly among different regions and health systems. Some specialized treatments may have limited access or require special approvals. Patients should consult hematologists about therapeutic options available in their local health systems, also considering participation in clinical research protocols that may offer access to innovative treatments.

How long does treatment last?

AML treatment is prolonged and intensive, typically divided into phases. Induction chemotherapy lasts approximately 4-6 weeks, aiming to achieve complete remission. This is followed by consolidation therapy with multiple cycles over 4-6 months. Patients who are candidates for bone marrow transplantation face an additional process that may extend for 6-12 months including preparation, transplantation, and recovery. Post-treatment follow-up with minimal residual disease monitoring and relapse surveillance continues for years. The total time from diagnosis to completion of active treatment varies from 6 months to more than one year, depending on the protocol and individual response.

Can this code be used in medical certificates?

Yes, code 2A60 can and should be used in official medical documentation, including certificates, medical reports, work leave requests, and documents for social security purposes. Acute myeloid leukemia constitutes an incapacitating condition during treatment, justifying absence from professional and school activities. Documentation should include the ICD-11 code 2A60, clear diagnostic description, disease stage, and proposed treatment. For legal and social security purposes, detailed reports from the responsible hematologist are frequently necessary, documenting the severity of the condition and temporary or permanent disability resulting from it.

What is the difference between AML and chronic myeloid leukemia?

They are fundamentally different diseases despite similar nomenclature. Chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome (translocation t(9;22) producing BCR-ABL1), proliferation of mature myeloid cells, indolent clinical course in chronic phase, and treatment with tyrosine kinase inhibitors. AML presents with proliferation of immature blasts (≥20%), aggressive course with rapid progression, absence of Philadelphia chromosome (except in rare cases of CML transformation), and treatment with intensive chemotherapy. They are coded in completely distinct categories in ICD-11.

Is AML hereditary or contagious?

AML is not contagious and cannot be transmitted between people. Most cases are sporadic, without an identifiable cause. However, there are rare genetic syndromes that increase the risk of developing AML, such as Down syndrome, Fanconi anemia, Bloom syndrome, and some germline mutations in genes such as CEBPA, RUNX1, or GATA2. Family history of AML is uncommon, but when present, may warrant genetic counseling. Acquired risk factors include prior exposure to chemotherapy or radiotherapy, occupational exposure to benzene and other chemicals, smoking, and advanced age.

How to differentiate AML from other causes of pancytopenia?

Pancytopenia (simultaneous reduction of hemoglobin, leukocytes, and platelets) has multiple causes beyond AML. Differentiation is based on the presence of blasts in peripheral blood or bone marrow (≥20% confirms AML), morphologic characteristics of cells, immunophenotyping, and clinical context. Bone marrow aplasia presents with hypocellular marrow without blasts. Nutritional deficiencies (vitamin B12, folate) cause pancytopenia with megaloblastic marrow. Myelodysplastic syndromes have blasts <20% with dysplasia. Bone marrow infiltration by solid tumors or lymphomas shows non-myeloid neoplastic cells. Bone marrow aspiration with complementary studies is essential for accurate differential diagnosis.

Can patients with AML receive vaccines?

During intensive chemotherapy treatment for AML, the immune system becomes severely compromised, contraindicating live attenuated virus vaccines (measles, mumps, rubella, varicella, yellow fever) due to the risk of vaccine disease. Inactivated vaccines are generally safe but may have reduced efficacy during immunosuppression. After bone marrow recovery and immune reconstitution, especially post-transplant, there is a protocol for progressive revaccination. Family members and close contacts should maintain updated vaccination, including annual influenza, to protect the immunosuppressed patient. Decisions about vaccination should be individualized in consultation with the responsible hematologist, considering timing, vaccine type, and current immune status.

Final note: This article provides general guidance on ICD-11 coding for acute myeloid leukemia and related precursor cell neoplasms. Accurate coding requires individualized evaluation of each case by qualified professionals, considering all available clinical, laboratory, and anatomopathological documentation. In complex or atypical situations, consultation with hematologists, hematopathologists, and medical coding specialists is recommended to ensure appropriate classification.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Acute myeloid leukemia and precursor cell neoplasms related

Compartilhar